CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Eton Pharmaceuticals

Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living with rare diseases.

Integrated Nano-Technologies

Integrated Nano-Technologies is a Henrietta, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adherium

Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.

Standard Bariatrics

Cincinnati-based surgical procedure company focused on innovative development, commercialization of medical devices for treatment of obesity, gastrectomy.

Cabrellis

Cabrellis is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.